Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 2/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367080 | 0.99 | GPR4 (0.54) | GPR4AGTR1AGTR2 | |
| SCHEMBL4320368 | 0.83 | AGTR1 (0.42) | GPR4AGTR1AGTR2 | |
| SCHEMBL4323454 | 0.83 | GPR4 (0.52) | GPR4 | |
| SCHEMBL4323458 | 0.83 | GPR4 (0.53) | GPR4 | |
| SCHEMBL6046535 | 0.83 | GPR4 (0.71) | GPR4AGTR1AGTR2 | |
| SCHEMBL5430126 | 0.82 | GPR4 (0.61) | GPR4AGTR1AGTR2 | |
| SCHEMBL4320371 | 0.82 | GPR4 (0.42) | GPR4AGTR1AGTR2 | |
| SCHEMBL13578531 | 0.82 | GPR4 (0.52) | GPR4 | |
| SCHEMBL4323461 | 0.81 | GPR4 (0.53) | GPR4 | |
| SCHEMBL13634003 | 0.79 | GPR4 (0.58) | GPR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| WO-2009144201-A1 | IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009144201-A1 | IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-12-03 | — | — | WO | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | GPR4, FABP6, GIPR | GPR4 1/4885AGTR1 843/4885AGTR2 759/4885 |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | FLT4, UACA, FLT1 | GPR4 119/4885AGTR1 819/4885AGTR2 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.